Triple-site Biventricular Stimulation in the Optimization of CRT

Heart Failure Clinical Trial

— TRIUMPH-CRT  

Official title:

Triple-site Biventricular Stimulation in the Optimization of Cardiac Resynchronization Therapy (CRT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02350842
• Other study ID #: ICSY02
• Status: Completed
• Phase: N/A
• Start date: July 2015
• Est. completion date: April 25, 2018

Study information

• Verified date: March 2019
• Source: MicroPort CRM
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cardiac resynchronization is a recommended therapy for patients with advanced heart failure, under optimized medical treatment with reduced left ventricular ejection fraction and prolonged QRS, nevertheless, still 30% of the population do not respond to standard biventricular implantation.

Non-response can be explained by a combination of factors including sub-optimal patient selection, placement of the pacing lead over a zone of slow conduction, insufficient correction of mechanical dyssynchrony including sub-optimal lead implantation. Few data distinguish true non-responders from patients in which effective resynchronization was not delivered through standard biventricular implantation.

Triple-site cardiac resynchronization pacing (stimulation at three ventricular sites) has been proposed to improve synchrony and thus the response rate in (Cardiac Resynchronisation Therapy) CRT recipients.

Description:

The frequent failure of CRT in non-Left Bundle Branch Block (non-LBBB) patients is suspected to be due to more complex and heterogeneous forms of electrical/mechanical dyssynchronies needing more complex and individualized pacing configurations to be corrected.

Acute studies during implant show that standard biventricular pacing provides optimal mechanical improvement only in a minority of patients. In a peri-operative echo-guided leads placement procedure most of non-improved patients could be successfully mechanically resynchronized. A significant number of patients required optimized placement of right ventricular (RV) lead and/or triple-site configurations.

These studies led to the hypothesis that more complex and individualized pacing configurations (Triple-site biventricular) might increase the number of responders to CRT.

To assess this hypothesis, this study will be conducted in Class II-ambulatory IV patients indicated for CRT with wide QRS (≥ 140 ms) and non-LBBB. Patients will be randomized in a 1:1 configuration:

• Standard biventricular pacing (1 right ventricular/1 left ventricular (1RV/1LV)) through classical implantation procedure without peri-operative optimization

• Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance.

The objective of the optimization process is to improve LV efficiency and to decrease the left pre-ejection interval (LPEI, defined as the time interval between the onset of QRS and the onset of LV ejection) as much as possible compared with a standard biventricular configuration by moving a second right ventricular lead at different locations.

LPEI is simple to measure, with good inter- and intra-observer reproducibility and its utility has previously been strongly suggested.

Reduction in LPEI results in decreased duration of ventricular systole and is associated with improved LV filling and reduced interventricular delay.

The primary objective of this study is to demonstrate that individually optimized, triple-site biventricular pacing is superior to standard biventricular pacing in reverse ventricular modeling as demonstrated by Echo Left Ventricle End-Systolic Volume (LVESV) at 1 year in patients with non-LBBB morphology without increasing the risk of serious procedure and/or device related adverse events at 30 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: April 25, 2018
• Est. primary completion date: March 31, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• Stable heart failure with New York Heart Association (NYHA) functional class II, III or ambulatory IV

• Stable optimized medical regimen according to medical guidelines (No change in heart failure medication for at least 1 month prior to enrollment)

• Left ventricular ejection fraction (LVEF) = 35%

• Intrinsic QRS duration = 140 msec

• Non-typical left bundle branch block (LBBB) morphology on 12-lead surface ECG

• Signed and dated informed consent

Exclusion Criteria:

• Typical LBBB according to Strauss criteria

• Unstable heart failure

• Permanent or long-lasting persistent Atrial Fibrillation

• Unstable angina, acute Myocardial Infarction (MI), Coronary Artery Bypass-Grafting (CABG), or Percutaneous Transluminal Coronary Angioplasty (PTCA) within 90 days prior to enrollment (intervention)

• Conventional pacemaker indication

• Previous implant with a pacemaker or an Implantable Cardioverter-Defibrillator (ICD)

• Renal Failure (Glomerular filtration rate (GFR) < 30 ml/min/1.73m2)

• Pregnant women

• Already included in another clinical study that could confound the results of this study

• Life expectancy < 12 months

• Mechanical heart valve or indication for valve repair or replacement

• Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months)

• Heart transplant

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• triple-site biventricular pacing with peri-operative echo guidance
placement of the third lead by peri-operative echo guidance.
• standard biventricular pacing
standard biventricular pacing without optimization by echo guidance

Locations

Country	Name	City	State
France	CHRU Hopital Sud	Amiens
France	Clinique Rhone Durance	Avignon
France	Hopital Jean Minjoz Besançon	Besançon
France	CHRU Brest	Brest
France	Groupe hospitalier Paris Saint-Joseph	Paris
France	CHU Poitiers	Poitiers
France	CHU Hôpital Charles Nicolle	Rouen
France	CHU Toulouse, Hopital Rangueil	Toulouse
Germany	Universitaetsklinikum Schleswig Holstein	Kiel
Italy	Humanitas Cliniche Gavazzeni spa	Bergamo
Netherlands	Isala Zwolle	Zwolle
Portugal	CHCL - Hospital Santa Marta	Lisbon
Spain	Hospital de la Santa Creu i Sant Pau	Barcelona
Spain	Hospital Universitario La Fe	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
MicroPort CRM

Countries where clinical trial is conducted

France,  Germany,  Italy,  Netherlands,  Portugal,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	TriV pacing is superior to standard BiV pacing in reversing ventricular modeling as demonstrated by Echo LVESV at 12 months in pts. with non LBBB without increasing the risk of serious events at 30 days.	The efficacy endpoint for this study is the change in LVESV at twelve months post-implant between individually optimized, triple-site biventricular pacing and standard biventricular pacing.; LVESV is a standard marker of CRT effectiveness1. Echocardiographic data collected at twelve months follow-up will document the evolution of LVESV as compared to baseline in order to assess reverse ventricular remodeling.; The safety endpoint for this study is the rate of all serious procedure and/or device related events reported at thirty days post-implant.	12 months
Secondary	Evaluate serious device related complications at six and twelve months post-procedure.	A safety assessment will be performed, including all reported events collected for all enrolled patients.	6 and 12 months
Secondary	Evaluate reverse ventricular remodeling response based on additional echocardiographic measures	Change in LV volumes and LV ejection fraction will be evaluated as part of reverse remodeling response, based on echocardiographic measurements: LVESV at 6 months; LVEDV at 6 and 12 months; LVEF at 6 and 12 months	6 and 12 months
Secondary	Evaluate patient's clinical status considering New York Heart Association (NYHA) functional class improvement	A patient's clinical status will be evaluated considering: NYHA functional class improvement - The evaluation of the NYHA classification consists of reporting the percentage of patients who improved at least one NYHA class at each follow-up post-implant.; Death from any cause - The reporting of deaths occurred consists of the percentage of dead patients, the causes of death, the time to death and survival curves.; HF-related hospitalizations, as defined in section 15.4.; The incidence of serious device related events assessed at six and twelve months.	6 and 12 months
Secondary	Evaluate mortality and serious heart failure (HF) events during the procedure through discharge and at the different follow-up time-points.	A safety assessment will be performed, including all reported events collected for all enrolled patients.	1, 6 and 12 months